Interaction of Docetaxel ("Taxotere") with Human P-glycoprotein
Overview
Affiliations
The interaction of docetaxel ("Taxotere") with P-glycoprotein (P-gp) was examined using porcine kidney epithelial LLC-PK1 and LLC-GA5-COL150 cells, overexpressing human P-gp selectively on the apical plasma membrane by transfection of human MDR1 cDNA into the LLC-PK1 cells. The basal-to-apical transport of [14C]docetaxel in LLC-GA5-COL150 cells significantly exceeded that in LLC-PK1 cells, but the apical-to-basal transport was decreased in LLC-GA5-COL150 cells. The intracellular accumulation after its basal or apical application to LLC-GA5-COL150 cells was 4- to 20-fold lower than that of LLC-PK1 cells. Multidrug resistance (MDR) modulators, i.e., cyclosporin A and SDZ PSC 833, inhibited the basal-to-apical transport and increased the apical-to-basal transport of [14C]docetaxel in LLC-GA5-COL150 cells, but verapamil affected only apical-to-basal transport. The intracellular accumulation after basal or apical application to LLC-GA5-COL150 cells was also increased by these three MDR modulators. These observations demonstrated that docetaxel is a substrate for human P-gp, suggesting that docetaxel-drug interactions occur via P-gp. The inhibition of [14C]docetaxel transport by the MDR modulators, as well as daunorubicin and vinblastine, was also found in LLC-PK1 cells, which endogenously express P-gp at lower levels, and concentrations showing similar levels of inhibition were lower than those in the case of LLC-GA5-COL150 cells. These observations indicate that it is necessary to consider the pharmacokinetic and pharmacodynamic interactions of docetaxel via P-gp.
Wang Y, Tu M, Yu A Front Pharmacol. 2024; 15:1423416.
PMID: 39114355 PMC: 11303158. DOI: 10.3389/fphar.2024.1423416.
Li T, Zhou S, Wang L, Zhao T, Wang J, Shao F J Pharmacokinet Pharmacodyn. 2024; 51(4):367-384.
PMID: 38554227 DOI: 10.1007/s10928-024-09912-z.
Marie S, Frost K, Hau R, Martinez-Guerrero L, Izu J, Myers C Acta Pharm Sin B. 2023; 13(1):1-28.
PMID: 36815037 PMC: 9939324. DOI: 10.1016/j.apsb.2022.08.018.
Nunes M, Duarte D, Vale N, Ricardo S Int J Mol Sci. 2023; 24(1).
PMID: 36613537 PMC: 9820586. DOI: 10.3390/ijms24010097.
Demeule M, Charfi C, Currie J, Zgheib A, Danalache B, Beliveau R Pharmaceutics. 2022; 14(9).
PMID: 36145658 PMC: 9503230. DOI: 10.3390/pharmaceutics14091910.